Rituximab: modes of action, remaining dispute and future perspective
- Author
- Abdulmunem Abulayha, Amin Bredan (UGent) , Hesham El Enshasy and Ian Daniels
- Organization
- Abstract
- Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.
- Keywords
- rituximab, NON-HODGKINS-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, caspases, mechanism, cell death, apoptosis, ANTI-CD20 MONOCLONAL-ANTIBODY, B-CELL LYMPHOMA, FC-GAMMA-RIIIA, DRUG-INDUCED APOPTOSIS, FAS-INDUCED APOPTOSIS, IN-VIVO, SIGNALING PATHWAY, PHASE-I
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 1.43 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-5930159
- MLA
- Abulayha, Abdulmunem, et al. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” FUTURE ONCOLOGY, vol. 10, no. 15, 2014, pp. 2481–92, doi:10.2217/fon.14.146.
- APA
- Abulayha, A., Bredan, A., El Enshasy, H., & Daniels, I. (2014). Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY, 10(15), 2481–2492. https://doi.org/10.2217/fon.14.146
- Chicago author-date
- Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, and Ian Daniels. 2014. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” FUTURE ONCOLOGY 10 (15): 2481–92. https://doi.org/10.2217/fon.14.146.
- Chicago author-date (all authors)
- Abulayha, Abdulmunem, Amin Bredan, Hesham El Enshasy, and Ian Daniels. 2014. “Rituximab: Modes of Action, Remaining Dispute and Future Perspective.” FUTURE ONCOLOGY 10 (15): 2481–2492. doi:10.2217/fon.14.146.
- Vancouver
- 1.Abulayha A, Bredan A, El Enshasy H, Daniels I. Rituximab: modes of action, remaining dispute and future perspective. FUTURE ONCOLOGY. 2014;10(15):2481–92.
- IEEE
- [1]A. Abulayha, A. Bredan, H. El Enshasy, and I. Daniels, “Rituximab: modes of action, remaining dispute and future perspective,” FUTURE ONCOLOGY, vol. 10, no. 15, pp. 2481–2492, 2014.
@article{5930159, abstract = {{Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.}}, author = {{Abulayha, Abdulmunem and Bredan, Amin and El Enshasy, Hesham and Daniels, Ian}}, issn = {{1479-6694}}, journal = {{FUTURE ONCOLOGY}}, keywords = {{rituximab,NON-HODGKINS-LYMPHOMA,CHRONIC LYMPHOCYTIC-LEUKEMIA,caspases,mechanism,cell death,apoptosis,ANTI-CD20 MONOCLONAL-ANTIBODY,B-CELL LYMPHOMA,FC-GAMMA-RIIIA,DRUG-INDUCED APOPTOSIS,FAS-INDUCED APOPTOSIS,IN-VIVO,SIGNALING PATHWAY,PHASE-I}}, language = {{eng}}, number = {{15}}, pages = {{2481--2492}}, title = {{Rituximab: modes of action, remaining dispute and future perspective}}, url = {{http://doi.org/10.2217/fon.14.146}}, volume = {{10}}, year = {{2014}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: